Ponatinib (AP24534) inhibits MEKK3-KLF signaling and prevents formation and progression of cerebral cavernous malformations-Reference-Cited by-同舟云学术

Ponatinib (AP24534) inhibits MEKK3-KLF signaling and prevents formation and progression of cerebral cavernous malformations

Published:2018-11-02 Issue:11 Volume:4 Page:
ISSN:2375-2548
Container-title:Science Advances
language:en
Short-container-title:Sci. Adv.

Author:

Choi Jaesung P.¹^ORCID,Wang Rui²^ORCID,Yang Xi²^ORCID,Wang Xian¹^ORCID,Wang Lu³^ORCID,Ting Ka Ka⁴,Foley Matthew⁵^ORCID,Cogger Victoria⁶^ORCID,Yang Zhuo⁷^ORCID,Liu Feng³^ORCID,Han Zhiming³,Liu Renjing⁸,Baell Jonathan⁹,Zheng Xiangjian¹²^ORCID

Affiliation:

1. Laboratory of Cardiovascular Signaling, Centenary Institute, and Sydney Medical School, University of Sydney, Sydney, NSW 2050, Australia.

2. Department of Pharmacology, School of Basic Medical Sciences, Tianjin Medical University, Tianjin 300070, China.

3. Institute of Zoology, Chinese Academy of Sciences, Beijing, China.

4. Centre for the Endothelium, Centenary Institute, and Sydney Medical School, University of Sydney, Sydney, NSW 2050, Australia.

5. Australian Centre for Microscopy & Microanalysis, University of Sydney, Sydney, NSW 2006, Australia.

6. ANZAC Research Institute, University of Sydney, Sydney, NSW, Australia.

7. Shanghai Institute of Biological Sciences, Chinese Academy of Sciences, Shanghai, China.

8. Agnes Ginges Laboratory for Diseases of the Aorta, Centenary Institute, and Sydney Medical School, University of Sydney, Sydney, NSW 2050, Australia.

9. Monash Institute of Pharmaceutical Sciences, Monash University, Melbourne, Australia.

Abstract

Ponatinib, a cancer drug, inhibits occurrence and growth of cerebral cavernous malformation in mouse models.

Funder

National Health and Medical Research Council

National Heart Foundation of Australia

National Natural Science Foundation of China

Publisher

American Association for the Advancement of Science (AAAS)

Subject

Multidisciplinary

Reference40 articles.

1. Incidental findings on brain MRI in the general population;Vernooij M. W.;N. Engl. J. Med.,2007

2. Cerebral cavernous malformations: From CCM genes to endothelial cell homeostasis;Fischer A.;Trends Mol. Med.,2013

3. CCM1 and CCM2 protein interactions in cell signaling: Implications for cerebral cavernous malformations pathogenesis;Stalheim L.;Hum. Mol. Genet.,2005

4. Regulation of cardiovascular development and integrity by the heart of glass-cerebral cavernous malformation protein pathway;Kleaveland B.;Nat. Med.,2009

5. CCM3 signaling through sterile 20-like kinases plays an essential role during zebrafish cardiovascular development and cerebral cavernous malformations;Zheng X.;J. Clin. Invest.,2010

Cited by 35 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Plxnd1-mediated mechanosensing of blood flow controls the caliber of the Dorsal Aorta via the transcription factor Klf2;2024-01-25

2. Bestrophin3 Deficiency in Vascular Smooth Muscle Cells Activates MEKK2/3–MAPK Signaling to Trigger Spontaneous Aortic Dissection;Circulation;2023-08-15

3. Kinases in cerebral cavernous malformations: Pathogenesis and therapeutic targets;Biochimica et Biophysica Acta (BBA) - Molecular Cell Research;2023-08

4. Impaired retinoic acid signaling in cerebral cavernous malformations;Scientific Reports;2023-04-05

5. Release of STK24/25 suppression on MEKK3 signaling in endothelial cells confers cerebral cavernous malformation;JCI Insight;2023-03-08